Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maintenance alemtuzumab in refractory chronic lymphocytic leukaemia.

Trial Profile

Maintenance alemtuzumab in refractory chronic lymphocytic leukaemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2010 Actual number of patients (12) added as reported by ClinicalTrials.gov record.
    • 19 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 11 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top